Humacyte Q4 EPS $(0.24), Inline; Humacyte Says Its Cash And Cash Equivalents Of $80.4M, Net Proceeds Of $43.1M From The March Offering And Additional Draw Of $20M Under The Oberland Funding Arrangement, Will Provide Cash Runway For At Least 12 Months
Humacyte第四季度每股收益为0.24美元（0.24），内联；Humacyte表示，其现金及现金等价物为8,040万美元，3月份发行的净收益为4,310万美元，以及根据Oberland融资安排额外提取的2000万美元，将为至少12个月的现金流提供资金